Abstract
We examined the efficacy of interferon (IFN) therapy for chronic hepatitis C (CHC) in view of the change of liver histology and iron staining before and after IFN therapy.
Enrolled in this study were 109 patients with CHC who completed IFN treatment and were followed for at least 1 yr after the end of IFN therapy. Serum iron, unsaturated-iron-binding capacity (UIBC), and total-iron-binding capacity (TIBC) were assessed before IFN therapy. Knodell’s histological activity index (HAI) score and iron staining were examined in 55 patients in whom liver biopsy was performed at two points: before and 1 yr after IFN therapy. Serum iron levels before IFN therapy did not correlate with the response to IFN. The HAI score significantly decreased after IFN therapy in complete responders (p<0.01) and biochemical responders (p<0.01). Three factors in the HAI, periportal necrosis, intralobular necrosis, and portal inflammation, but not fibrosis, were significantly decreased in complete responders (p<0.01) and biochemical responders (p<0.01). Of 55 patients, 23 (41.8%) were positive for iron staining before IFN therapy and 14 of 55 (25.5%) after IFN therapy. The positive rate for iron staining tended to decrease after IFN therapy, not correlating to the response to IFN, but the change was not statistically significant.
In conclusion, the histological improvement by IFN therapy was mostly seen in necroinflammatory changes but not in fibrosis at least 1 yr after IFN, and iron staining tended to decrease after IFN therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
B. K. Hudes, T. L. Fabry, and F. M. Klion, Hepatic iron metabolism in chronic hepatitis C, Hepatology 16, 206A (abstract) (1992).
H. Hayashi, T. Takikawa, N. Nishimura, M. Yano, T. Isomura, and N. Sakamoto, Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron, Am. J. Gastroenterol. 89, 986–988 (1994).
H. Okamoto, Y. Sugiyama, S. Okada, K. Kurai, Y. Akahane, Y. Sugai, et al., Typing hepatitis C virus by polymerase chain reaction with type-specific primers; application to clinical surveys and tracing infections sources, J. Gen. Virol. 73, 673–679 (1992).
R. G. Knodell, K. G. Ishak, W. C. Black, T. S. Chen, R. Craig, N. Kaplowitz, et al., Formation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis, Hepatology 1, 431–435 (1981).
C. Camma, M. Giunta, C. Linea, and L. Pagliaro, The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis, J. Hepatol. 26, 1187–1199 (1997).
A. Tsubota, H. Kumada, K. Chayama, Y. Arase, S. Saitoh, I. Koida, et al., Time course of histological changes in patients with a sustained biochemical and virological response to interferon-α therapy for chronic hepatitis C virus infection, J. Hepatol. 27, 49–55 (1997).
J. A. Garson, I. Uhnoo, K. Whitby, J. H. Braconier, R. Deaville, A. Duberg, et al., Virological, biochemical and histological effects of human lymphoblastoid interferon in Swedish patients with chronic hepatitis C, J. Viral Hepatol. 4, 325–331 (1997).
P. A. Bonis, J. P. Ioannidis, J. C. Cappelleri, M. M. Kaplan, and J. Lau, Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: a meta-analysis of diagnostic test characteristics, Hepatology 26, 1035–1044 (1997).
A. Piperno, M. Sampietro, R. D’Alba, L. Roffi, S. Fargion, S. Parma, et al., Iron stores, response to α-interferon therapy, and effects of iron depletion in chronic hepatitis C, Liver 16, 248–254 (1996).
D. H. Van Thiel, L. Friedlander, S. Fagiuoli, H. I. Wright, W. Irish, and J. S. Gavaler, Response to interferon-α therapy is influenced by the iron content of the liver, J. Hepatol. 20, 410–415 (1994).
F. Akiyoshi, M. Sata, Y. Uchimura, H. Suzuki, and K. Tanikawa, Hepatic iron stainings in chronic hepatitis C patients with low HCV RNA levels: a predictive marker for IFN therapy, Am. J. Gastroenterol. 92, 1463–1466 (1997).
Y. M. Deugnier, B. Turlin, L. W. Powell, K. M. Summers, R. Moirand, L. Fletcher, et al., Differentiation between heterozygotes and homozygotes in genetic hemochromatosis by means of a histological hepatic iron index: a study of 192 cases, Hepatology 17, 30–34 (1993).
E. Boucher, A. Bourienne, P. Adams, B. Turlin, P. Brissot, and Y. Deugnier, Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment, Gut 41, 115–120 (1997).
P. Scheuer, Viral hepatitis, in Pathology of the Liver, R. MacSween, P. Anthony, and P. Scheuer, eds., Churchill Livingstone, London, pp. 201–223 (1988).
R. Taetle and M. Honeystt, γ-Interferon modulates human monocyte/macrophage transferrin receptor expression, Blood 71, 1590–1595 (1988).
D. H. Van Thiel, L. Friedlander, P. J. Molloy, R. J. Kania, S. Fagiuoli, H. I. Wright, et al., Retreatment of hepatitis C interferon non-responders with large doses of interferon with and without phlebotomy, Hepato-Gastroenterology 43, 1557–1561 (1996).
H. L. Bonkovsky, Therapy of hepatitis C: other options, Hepatology 26, 143S-151S (1997).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kakizaki, S., Takagi, H., Ichikawa, T. et al. Histological change after interferon therapy in chronic hepatitis C in view of iron deposition in the liver. Biol Trace Elem Res 73, 151–162 (2000). https://doi.org/10.1385/BTER:73:2:151
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/BTER:73:2:151